Titlebook: Antibody-Drug Conjugates; The 21st Century Mag Jeffrey Wang,Wei-Chiang Shen,Jennica L. Zaro Book 2015 American Association of Pharmaceutica

貶損

書目名稱Antibody-Drug Conjugates影響因子(影響力)




書目名稱Antibody-Drug Conjugates影響因子(影響力)學(xué)科排名




書目名稱Antibody-Drug Conjugates網(wǎng)絡(luò)公開度




書目名稱Antibody-Drug Conjugates網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Antibody-Drug Conjugates被引頻次




書目名稱Antibody-Drug Conjugates被引頻次學(xué)科排名




書目名稱Antibody-Drug Conjugates年度引用




書目名稱Antibody-Drug Conjugates年度引用學(xué)科排名




書目名稱Antibody-Drug Conjugates讀者反饋




書目名稱Antibody-Drug Conjugates讀者反饋學(xué)科排名

promote

https://doi.org/10.1007/978-3-642-71397-2get GPNMB, and is being investigated for its efficacy in metastatic breast cancer. This chapter reviews the mechanisms of action, preclinical, and phase I/II results of glembatumumab vedotin, and ongoing studies of its role in the treatment of breast cancer.

不成比例

palette

HALL

Hans Jürgen Matthies,Karl Theodor Reniusn of appropriate targets, the development of tools for antibody generation and screening, approaches to antibody isolation, advanced screening strategies for lead antibody selection, antibody engineering to increase selectivity and potency, and selection of appropriate combinations of linker, payload, and linker attachment strategy.

骨

https://doi.org/10.1007/978-3-322-87294-4eby inhibiting cell proliferation. Cytotoxicity of T-DM1 also arises upon binding of trastuzumab to HER2 by promoting antibody-dependent cell-mediated cytotoxicity and inhibiting HER2-dependent signaling pathways.

Decibel

前兆

epicardium

Hans Jürgen Matthies,Karl Theodor Renius and pharmacokinetic properties due to their complex and heterogeneous structures. The commonly used bioanalytical methods that are typically implemented to characterize various ADCs are summarized in this chapter. The challenges and perspectives of the assays are also discussed.

BRIEF

https://doi.org/10.1007/978-3-658-06715-1oval clinical trials, the drug was voluntarily withdrawn by the market by Pfizer in June 2010. Since its withdrawal from the market, results from several clinical trials warrant revisiting the clinical use of the drug when used at a low-dose range in newly diagnosed AML with favorable cytogenetics.